Modern options in personalized therapy of metastatic cutaneous melanoma
A great progress was recently achieved in metastatic melanoma therapy. New targeted therapies allow high efficacy expectations for personalized treatment approaches. BRAF-inhibitors significantly increase time to progression, overall survival and response rate in malignant melanoma patients. Vemuraf...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2014-09-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26968 |
| _version_ | 1818891239858110464 |
|---|---|
| author | S A Protsenko A V Novik Z Yu Akhaeva A S Zhabina E N Imyanitov A I Semenova |
| author_facet | S A Protsenko A V Novik Z Yu Akhaeva A S Zhabina E N Imyanitov A I Semenova |
| author_sort | S A Protsenko |
| collection | DOAJ |
| description | A great progress was recently achieved in metastatic melanoma therapy. New targeted therapies allow high efficacy expectations for personalized treatment approaches. BRAF-inhibitors significantly increase time to progression, overall survival and response rate in malignant melanoma patients. Vemurafenib is the first registered in Russia drug of this type. Current clinical data review on vemurafenib is presented in this paper. |
| first_indexed | 2024-12-19T17:37:39Z |
| format | Article |
| id | doaj.art-7aa4b734c2694d1c97e040d1d88669b8 |
| institution | Directory Open Access Journal |
| issn | 1815-1434 1815-1442 |
| language | Russian |
| last_indexed | 2024-12-19T17:37:39Z |
| publishDate | 2014-09-01 |
| publisher | IP Habib O.N. |
| record_format | Article |
| series | Современная онкология |
| spelling | doaj.art-7aa4b734c2694d1c97e040d1d88669b82022-12-21T20:12:17ZrusIP Habib O.N.Современная онкология1815-14341815-14422014-09-01163576424188Modern options in personalized therapy of metastatic cutaneous melanomaS A ProtsenkoA V NovikZ Yu AkhaevaA S ZhabinaE N ImyanitovA I SemenovaA great progress was recently achieved in metastatic melanoma therapy. New targeted therapies allow high efficacy expectations for personalized treatment approaches. BRAF-inhibitors significantly increase time to progression, overall survival and response rate in malignant melanoma patients. Vemurafenib is the first registered in Russia drug of this type. Current clinical data review on vemurafenib is presented in this paper.https://modernonco.orscience.ru/1815-1434/article/view/26968metastatic melanomatargeted therapybraf-inhibitorsvemurafenib |
| spellingShingle | S A Protsenko A V Novik Z Yu Akhaeva A S Zhabina E N Imyanitov A I Semenova Modern options in personalized therapy of metastatic cutaneous melanoma Современная онкология metastatic melanoma targeted therapy braf-inhibitors vemurafenib |
| title | Modern options in personalized therapy of metastatic cutaneous melanoma |
| title_full | Modern options in personalized therapy of metastatic cutaneous melanoma |
| title_fullStr | Modern options in personalized therapy of metastatic cutaneous melanoma |
| title_full_unstemmed | Modern options in personalized therapy of metastatic cutaneous melanoma |
| title_short | Modern options in personalized therapy of metastatic cutaneous melanoma |
| title_sort | modern options in personalized therapy of metastatic cutaneous melanoma |
| topic | metastatic melanoma targeted therapy braf-inhibitors vemurafenib |
| url | https://modernonco.orscience.ru/1815-1434/article/view/26968 |
| work_keys_str_mv | AT saprotsenko modernoptionsinpersonalizedtherapyofmetastaticcutaneousmelanoma AT avnovik modernoptionsinpersonalizedtherapyofmetastaticcutaneousmelanoma AT zyuakhaeva modernoptionsinpersonalizedtherapyofmetastaticcutaneousmelanoma AT aszhabina modernoptionsinpersonalizedtherapyofmetastaticcutaneousmelanoma AT enimyanitov modernoptionsinpersonalizedtherapyofmetastaticcutaneousmelanoma AT aisemenova modernoptionsinpersonalizedtherapyofmetastaticcutaneousmelanoma |